Cardima out of woods with $4.5m private placement:
This article was originally published in Clinica
Executive Summary
A private placement grossing $4.5m in proceeds has set Cardima en route to redeeming itself from a potential Nasdaq delisting. The money will enable the Fremont, California company to raise its stockholder's equity in excess of the minimum $2.5m required to remain trading on the US stock exchange. Cardima received a delisting warning from Nasdaq last month (see Clinica No 1134, p 12) and will be submitting its plans to regain and maintain compliance to Nasdaq's other listing requirements.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.